Detalles de la búsqueda
1.
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.
BMC Gastroenterol
; 19(1): 21, 2019 Feb 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30717682
2.
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition.
J Thorac Oncol
; 19(1): 160-165, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37429463
3.
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors.
Eur J Cancer
; 179: 124-135, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36521334
4.
Corrigendum: Abscopal Effects in Radio-Immunotherapy-Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition.
Front Pharmacol
; 10: 1615, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-32082149
5.
Abscopal Effects in Radio-Immunotherapy-Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition.
Front Pharmacol
; 10: 511, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31156434
6.
Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.
Lung Cancer
; 133: 20-22, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31200822
7.
Successful Yttrium-90 Microsphere Radioembolization for Hepatic Metastases of Prostate Cancer.
Case Rep Oncol
; 10(2): 627-633, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28868022
8.
Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC.
JCO Precis Oncol
; 2: 1-6, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35135141
Resultados
1 -
8
de 8
1
Próxima >
>>